Abstract
Yuki Tahira, Kotaro Shide, Takuro Kameda, Taisuke Uchida, Ayako Kamiunten, Keiichi Akizuki, Yoko Kubuki, Masayoshi Karasawa, Ryoma Ikeda, Minoru Terashima, Koji Kato, Tomofumi Uto, Tomohiro Fukaya, Shuya Mitoma, Katsuaki Sato, Yudai Uehira, Hiroaki Ueno, Goro Sashida, Hideki Yamaguchi
Abstract
Rights: UNKNOWN · cc-by-nc-nd · Source: journal-auto-sync:external:CROSSREF_ISSN
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
doaj
Confidence 92%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Unresolved referenced work
2017
Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms
10.1182/blood-2016-10-695940 · 2017
Evaluation of therapeutic strategies to reduce the number of thrombotic events in patients with polycythemia vera and essential thrombocythemia
10.3389/fonc.2020.636675 · 2021
Role of JAK inhibitors in myeloproliferative neoplasms: current point of view and perspectives
10.1007/s12185-022-03335-7 · 2022
Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera
10.1182/blood-2008-03-143537 · 2008
Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera
10.1200/jco.2009.23.6075 · 2009
Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg-proline-interferon alpha-2b
10.1002/ajh.23928 · 2015
Minimal residual disease and normalization of the bone marrow after long-term treatment with alpha-interferon2b in polycythemia vera. A report on molecular response patterns in seven patients in sustained complete hematological remission
10.1179/102453309x12473408860587 · 2009
Recombinant interferon-alpha for treatment of polycythaemia vera
10.1016/s0140-6736(88)92881-4 · 1988
Treatment of essential thrombocythaemia by alpha 2a interferon
10.1016/s0140-6736(88)92625-6 · 1988
Ropeginterferon alfa-2b induces high rates of clinical, hematological and molecular responses in polycythemia vera: two-year results from the first prospective randomized controlled trial
2017
Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study
10.1016/s2352-3026(19)30236-4 · 2020
Interferons and their actions
10.1146/annurev.bi.56.070187.003455 · 1987
The neglected role of type I interferon in the T-cell response: implications for its clinical use
10.1016/0167-5699(96)10027-x · 1996
Antiproliferative properties of type I and type II interferon
10.3390/ph3040994 · 2010
Review: IFN-alpha/beta receptor interactions to biologic outcomes: understanding the circuitry
10.1089/107999002760274845 · 2002
The protein tyrosine kinase JAK1 complements defects in interferon-alpha/beta and -gamma signal transduction
10.1038/366129a0 · 1993
Complementation by the protein tyrosine kinase JAK2 of a mutant cell line defective in the interferon-gamma signal transduction pathway
10.1038/366166a0 · 1993
Cytokine receptor signalling
10.1038/377591a0 · 1995
Genetic transfer of a functional human interferon alpha receptor into mouse cells: cloning and expression of its cDNA
10.1016/0092-8674(90)90738-z · 1990
Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins
10.1126/science.8197455 · 1994
Mutant U5A cells are complemented by an interferon-alpha beta receptor subunit generated by alternative processing of a new member of a cytokine receptor gene cluster
10.1002/j.1460-2075.1995.tb00192.x · 1995
Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses
10.1016/s0092-8674(00)81166-6 · 1998
Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway
10.1016/s0092-8674(00)81288-x · 1996
Tyk2 plays a restricted role in IFN alpha signaling, although it is required for IL-12-mediated T cell function
10.1016/s1074-7613(00)00055-8 · 2000
Cutting edge: tyk2 is required for the induction and nuclear translocation of Daxx which regulates IFN-alpha-induced suppression of B lymphocyte formation
10.4049/jimmunol.169.9.4707 · 2002
Intracellular signal transduction of interferon on the suppression of haematopoietic progenitor cell growth
10.1046/j.1365-2141.2003.04650.x · 2003
Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F
10.1038/sj.leu.2405043 · 2008
Loss of tyrosine kinase 2 does not affect the severity of Jak2V617F-induced murine myeloproliferative neoplasm
2017
Neoplastic fibrocytes play an essential role in bone marrow fibrosis in Jak2V617F-induced primary myelofibrosis mice
10.1038/s41375-020-0880-3 · 2021
Multifaceted activities of type I interferon are revealed by a receptor antagonist
10.1126/scisignal.2004998 · 2014
Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-alpha in a murine model of polycythemia vera
10.1182/blood-2012-05-432989 · 2013
Ropeginterferon alfa-2b, a novel IFα-2b, induces high response rates with low toxicity in patients with polycythemia vera
10.1182/blood-2015-04-637280 · 2015
Distinct effects of ruxolitinib and interferon-alpha on murine JAK2V617F myeloproliferative neoplasm hematopoietic stem cell populations
10.1038/s41375-019-0638-y · 2020
JAK2-V617F and interferon-alpha induce megakaryocyte-biased stem cells characterized by decreased long-term functionality
10.1182/blood.2020005563 · 2021
Type I interferon: friend or foe?
10.1084/jem.20101664 · 2010
A critical function for type I interferons in cancer immunoediting
10.1038/ni1213 · 2005
Type I IFN contributes to NK cell homeostasis, activation, and antitumor function
10.4049/jimmunol.178.12.7540 · 2007
Activation of Tyk2 and Stat3 is required for the apoptotic actions of interferon-beta in primary pro-B cells
10.1074/jbc.m509516200 · 2006
STAT1, STAT3 and p38MAPK are involved in the apoptotic effect induced by a chimeric cyclic interferon-α2b peptide
10.1016/j.yexcr.2009.11.016 · 2010
No additional external references are available.